This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Parenteral === The term parenteral is from para-1 'beside' + Greek enteron 'intestine' + -al. This name is due to the fact that it encompasses a route of administration that is not intestinal. However, in common English the term has mostly been used to describe the four most well-known routes of injection.
== Pharmacology == In tests with rabbits, a significant improvement in protection against arrhythmic effects and infarct size reduction was observed after administrating exogenously SRTX-c (in dosage of 0.24 nmol/kg, i.v.) prior the coronary occlusion accident. That was achieved thanks to the ability of SRTX-c to activate selected ETB receptors. In rat thoracic aorta, the contractile activity is grouped as follows: ET-1 > SRTX-b > SRTX-a > SRTX-c at lower concentrations, but SRTX-b > ET-1 > SRTX-a > SRTX-c at higher concentrations. Intra-arterial injections of SRTX-b cause a dose-dependent increase in perfusion pressure at doses ranging from 30 to 300 pmol. The vasoconstrictor activity of SRTX-b is less remarkable than that of ET-1 at doses lower than 100 pmol, while at a dose of 300 pmol the activity of SRTX-b is greater than that of ET-1. The time required for the recovery of perfusion pressure to baselines after a bolus injection of 300 pmol SRTX-b is shorter than that of ET-1. The threshold vasoconstrictor dose of SRTX-a is 3 times larger than that of SRTX-b. At a dose of 300 pmol, the rise in perfusion pressure due to SRTX-a is about 8 times smaller than that of SRTX-b. SRTX-c exhibits a feeble vasoconstriction producing a very small increase in perfusion pressure.
Researchers and surgeons have conducted clinical and basic science studies to uncover the regenerative capacity possessed by the large animal species involved (humans and quadrupeds) for potential therapies to treat the disease. Some therapies, carried out by research laboratories in New York, include introduction of biologically engineered, injectable riboflavin cross-linked high density collagen (HDC-laden) gels into disease spinal segments to induce regeneration, ultimately restoring functionality and structure to the two main inner and outer components of vertebral discs—anulus fibrosus and the nucleus pulposus. A 2025 phase I clinical trial reported that intradiscal injection of autologous nucleus pulposus cells combined with endoscopic discectomy was safe in patients with chronic low back pain, with no serious adverse events over 24 months. The study also observed sustained improvements in pain, disability scores, and magnetic resonance imaging indicators of disc hydration and morphology.
== Role in hydrocarbon generation == When animal or plant matter is buried during sedimentation, the constituent organic molecules (lipids, proteins, carbohydrates and lignin-humic compounds) break down due to the increase in temperature and pressure. This transformation occurs in the first few hundred meters of burial and results in the creation of two primary products: kerogens and bitumens. It is generally accepted that hydrocarbons are formed by the thermal alteration of these kerogens (the biogenic theory). In this way, given certain conditions (which are largely temperature-dependent) kerogens will break down to form hydrocarbons through a chemical process known as cracking, or catagenesis. A kinetic model based on experimental data can capture most of the essential transformation in diagenesis, and a mathematical model in a compacting porous medium to model the dissolution-precipitation mechanism. These models have been intensively studied and applied in real geological applications. Diagenesis has been divided, based on hydrocarbon and coal genesis into: eodiagenesis (early), mesodiagenesis (middle) and telodiagenesis (late). During the early or eodiagenesis stage shales lose pore water, little to no hydrocarbons are formed and coal varies between lignite and sub-bituminous. During mesodiagenesis, dehydration of clay minerals occurs, the main development of oil genesis occurs and high to low volatile bituminous coals are formed. During telodiagenesis, organic matter undergoes cracking and dry gas is produced; semi-anthracite coals develop.
Sources: en.wikipedia.org
Animals, not humans, serve as reservoir species for rabies and are responsible for passing the virus to humans in the overwhelming majority of cases. Therefore to eliminate rabies in an area is to eliminate rabies from the local animal populations, both wild and domestic. Pre-exposure immunization has been used on domesticated and wild populations. In many jurisdictions, domestic dogs, cats, ferrets, and rabbits are required to be vaccinated.
==== Contact with anti-Chiang organizations ==== Liu was reportedly influenced by the Xi'an Incident and the formation of the Second United Front in 1936, noting that the Communist Party was emerging as a major force in the country. In 1938, Liu Wenhui then reportedly established contact with the Communist Party's Southern Bureau through his in-laws, including general Zhang Zhihe. Zhang Zhihe would become a member of the Central Committee of the China Democratic League (CDL). Another CDL Central Committee member he was in close contact with was Zheng Shufan. Around the time of its establishment in 1941, Liu began providing financial support to the CDL. In September 1944, Liu joined the China Democratic League, becoming a Central Committee member in 1945. Liu's membership, influenced by fellow Sichuan native and CDL chairman Zhang Lan, was kept secret. Peng Dixian, who would later become one of Liu's main biographers, asserts that he established a branch of the CDL in Xikang under Liu's auspices, serving as its chairman. Liu and the CDL would cooperate closely during the later Chengdu Uprising. Over the course of the war with Japan, Liu had also been in contact with generals Li Jishen and Feng Yuxiang, who established the Revolutionary Committee of the Chinese Kuomintang (RCCK) in January 1948. On the urging of Li Jishen, Liu joined in the summer of 1948 as an underground member of the RCCK, becoming the Chairman of its Sichuan branch.
== Further reading == Ye, Yanqi; Yu, Jicheng; Gu, Zhen (2015). "Versatile Protein Nanogels Prepared by In Situ Polymerization". Macromolecular Chemistry and Physics. 217 (3): 333–343. doi:10.1002/macp.201500296. Yan, Ming; Ge, Jun; Liu, Zheng; Ouyang, Pingkai (2006). "Encapsulation of Single Enzyme in Nanogel with Enhanced Biocatalytic Activity and Stability". Journal of the American Chemical Society. 128 (34): 11008–9. Bibcode:2006JAChS.12811008Y. doi:10.1021/ja064126t. PMID 16925402. Reese, Chad E.; Mikhonin, Alexander V.; Kamenjicki, Marta; Tikhonov, Alexander; Asher, Sanford A. (2004). "Nanogel Nanosecond Photonic Crystal Optical Switching". Journal of the American Chemical Society. 126 (5): 1493–6. Bibcode:2004JAChS.126.1493R. doi:10.1021/ja037118a. PMID 14759207. Lee, Eun Seong; Kim, Dongin; Youn, Yu Seok; Oh, Kyung Taek; Bae, You Han (2008). "A Virus-Mimetic Nanogel Vehicle". Angewandte Chemie International Edition. 47 (13): 2418–21. Bibcode:2008ACIE...47.2418L. doi:10.1002/anie.200704121. PMC 3118583. PMID 18236507. Hasegawa, Urara; Nomura, Shin-Ichiro M.; Kaul, Sunil C.; Hirano, Takashi; Akiyoshi, Kazunari (2005). "Nanogel-quantum dot hybrid nanoparticles for live cell imaging". Biochemical and Biophysical Research Communications. 331 (4): 917–21. Bibcode:2005BBRC..331..917H. doi:10.1016/j.bbrc.2005.03.228. PMID 15882965. Du, Jin-Zhi; Sun, Tian-Meng; Song, Wen-Jing; Wu, Juan; Wang, Jun (2010). "A Tumor-Acidity-Activated Charge-Conversional Nanogel as an Intelligent Vehicle for Promoted Tumoral-Cell Uptake and Drug Delivery".
Sources: en.wikipedia.org
==== Natural biocontrol and elicitor ==== In agriculture, chitosan is typically used as a natural seed treatment and plant growth enhancer, and as an ecologically friendly biopesticide substance that boosts the innate ability of plants to defend themselves against fungal infections. Degraded molecules of chitin/chitosan exist in soil and water. Chitosan applications for plants and crops are regulated in the USA by the Environmental Protection Agency, and the USDA National Organic Program regulates its use on organic certified farms and crops. EPA-approved, biodegradable chitosan products are allowed for use outdoors and indoors on plants and crops grown commercially and by consumers. In the European Union and United Kingdom, chitosan is registered as a "basic substance" for use as a biological fungicide and bactericide on a wide range of crops. The natural biocontrol ability of chitosan should not be confused with the effects of fertilizers or pesticides upon plants or the environment. Chitosan active biopesticides represent a new tier of cost-effective biological control of crops for agriculture and horticulture. The biocontrol mode of action of chitosan elicits natural innate defense responses within plant to resist insects, pathogens, and soil-borne diseases when applied to foliage or the soil. Chitosan increases photosynthesis, promotes and enhances plant growth, stimulates nutrient uptake, increases germination and sprouting, and boosts plant vigor.
Prioritize agricultural production of a diverse range of nutrient-rich foods; Protect nutrient-rich wild foods and species-rich ecosystems on land and in oceans; Support connectivity of smallholders and Small and Medium Sized Enterprises (SMEs) across food value chains; Redesign safety net/social protection programs towards improved nutritional outcome; Reduce food loss and food waste; Improve food quality and safety; Strengthen regulations for advertising and marketing; Improve transparency in food labeling; Encourage healthier eating through subsidies and promotions of healthy foods and taxes on unhealthy foods; Create consumer demand for healthy foods (nutrition education & civic engagement); Improve acceptability of healthy foods; Promote traditional foods and methods that impart nutritional benefits; Invest in metrics, research, and access to inform policy development.
Given their birth years, members of Generation Z have no memory of the time before the terrorist attacks on September 11, 2001, and the subsequent war on terror. Yet even twenty years after the attacks had taken place, concerns over national security as well as personal safety remain. But most members of Generation Z were in their formative years during the 2008 financial crisis. A 2013 survey found that 47% of Generation Z in the United States (considered here to be those between the ages of 14 and 23) were concerned about student debt, while 36% were worried about being able to afford a higher education at all. This generation is facing a growing income gap and a shrinking middle-class, which all have led to increasing stress levels in families. According to Public Relations Society of America, the Great Recession has taught Generation Z to be independent, and has led to an entrepreneurial desire, after seeing their parents and older siblings struggle in the workforce. Psychologist Jean Twenge describes Generation Z as "uniquely pessimistic" compared to older cohorts. The COVID-19 pandemic struck when the oldest members of Generation Z was just joining the workforce and the rest were still in school. For this reason, it split Generation Z into two small cohorts with drastically different lived experiences, and this gap has been widened by the rapid pace of technological change, not just video-sharing platforms—especially TikTok—but also generative artificial intelligence (AI) algorithms, notably ChatGPT.
=== Patient recorded data === Where the subject is required to record data (e.g. daily symptoms) then a diary is provided for completion. Data management of this data requires a different approach to CRF data as, for example, it is generally not practical to raise data queries. Patient diaries may be developed in either paper or electronic (eDiary) formats. Such eDiaries generally take the form of a handheld device which enables the subject to enter the required data and transmits this data to a centralised server.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.